Mepatar

Quick links to important sections

Mepatar

Method of action: Ophthalmologicals

Treatment option: Blepharitis, Keratitis, Trachoma

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mepatar

Quick Facts

Property Description
Active ingredient Oxytetracycline hydrochloride (Oxytetrazyklin Hydrochlorid)
Form Tablets, capsules, or parenteral solution
Pharmacological class Tetracycline antibiotic (Broad-spectrum antibacterial)
Common use Systemic bacterial anti-infection
Origin Naturally derived (Streptomyces rimosus)

Mepatar: Definition and Pharmacological Classification

Mepatar is a medicine containing the single active ingredient Oxytetrazyklin Hydrochlorid, which fundamentally defines it as a Tetracycline antibiotic. This widely recognized pharmacological class places it within the group of broad-spectrum antibacterial agents used to stop the proliferation of various bacterial strains. Oxytetracycline is classified on the Model List of Essential Medicines, reflecting its established role as a necessary antibiotic. This status signifies its importance in addressing key public health concerns related to bacterial infections.


Composition, Origin, and General Purpose

The core of Mepatar is Oxytetrazyklin Hydrochlorid, which is a single-ingredient product derived from natural processes, originally isolated from the Streptomyces rimosus bacterium. The active component functions primarily as a bacteriostatic agent. Its ability to inhibit the protein synthesis necessary for bacterial growth is a recognized property characteristic of the tetracycline class. The drug's primary action is to stall the infection, allowing the body's natural defenses time to eliminate the bacteria. The overall general purpose of Mepatar is to reduce the infectious load throughout the body, helping to resolve underlying bacterial illnesses, making it a typical agent employed in managing common community-acquired bacterial infections.


Available Pharmaceutical Forms

Mepatar is manufactured in multiple forms to ensure suitable administration, differentiating it based on the required route of delivery. These include tablets or capsules for oral administration, as well as a sterile aqueous solution intended for parenteral (injection) use. This versatility in pharmaceutical preparation, allowing for both convenient oral intake and rapid systemic delivery via injection, ensures that the drug can be introduced into the body effectively, depending on the clinical requirement. The formulation contains only the single active ingredient, which is a differentiating feature from combination antibiotic products.

Regulatory References

  1. WHO Essential Medicines List - Oxytetracycline entry

What side effects are possible with Mepatar?

Possible Side Effects and Safety Information

Adverse reactions associated with Mepatar (Oxytetracycline hydrochloride) are classified by regulatory agencies across several body systems. The officially documented adverse reaction scope includes Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, and Nervous System Disorders.

Frequency and Systemic Effects

Common effects documented in regulatory labeling often involve the gastrointestinal tract, such as nausea, vomiting, diarrhea, and stomach irritation. A notable common reaction is Photosensitivity, an increased sensitivity of the skin to sunlight, which is classified under skin and subcutaneous tissue disorders.

System-Organ Class Common/Expected Reactions
Gastrointestinal Nausea, vomiting, diarrhea, loss of appetite, dysphagia
Dermatological Photosensitivity reaction, rash, urticaria
Infections Overgrowth of non-susceptible organisms, including fungi

Serious Adverse Reactions and Safety Constraints

Regulatory documents list certain rare but serious reactions, including a severe elevation of pressure in the skull known as Benign Intracranial Hypertension (Pseudotumor Cerebri), and serious bowel inflammation such as Clostridioides difficile-associated diarrhea (CDAD).

The official safety profile features strict population-specific constraints. Mepatar is generally restricted during periods of active tooth development (infancy and childhood up to age 8-12) due to the documented risk of permanent discoloration and enamel hypoplasia. Similar constraints apply to pregnant individuals due to risks of fetal skeletal and dental harm, and documented concerns regarding maternal liver toxicity. Furthermore, use is contraindicated with certain medications, such as Retinoids (due to increased risk of intracranial hypertension), and in cases of severe renal impairment or known hypersensitivity to the tetracycline class.

Overdose and Emergency Response

Overdose and When to Seek Help

Overexposure to high doses of Mepatar is primarily associated with systemic organ toxicity. Regulatory documents specify the potential for Hepatotoxicity, which can manifest as hepatitis or hepatic failure, and Renal dysfunction or kidney injury. These toxicities are linked to high serum concentrations and may be indicated by laboratory abnormalities such as elevated blood urea nitrogen (BUN).

A particularly serious, regulator-documented neurological outcome is Benign Intracranial Hypertension (pseudotumor cerebri). Clinical manifestations of this include persistent headache and visual disturbance. The official instruction requires immediate cessation of treatment if these signs develop. Individuals with pre-existing renal or hepatic impairment are identified as a population at increased risk for toxicity due to potential drug accumulation.

Immediate Medical Protocol

In the event of a suspected overdose, the official regulatory mandate is to seek medical advice immediately and go to the accident and emergency department of your local hospital. Due to the nature of the drug, there is no known specific antidote. Management is strictly defined as being symptomatic and supportive, which may include procedures such as considering gastric lavage in the first hours following ingestion, alongside the oral administration of milk or antacids.

Therapeutic Uses of Mepatar

What Mepatar Treats: Main Uses and Benefits

Mepatar is commonly used in clinical settings to help with bacterial conditions, applied across domains where additional symptomatic support is needed. It is considered relevant in treating conditions associated with acute or disruptive episodes, such as pneumonia, acute bronchitis flare-ups, and conditions like typhus. Mepatar is applied in clinical settings that involve acute or unstable symptom patterns, including fever, chills, and malaise. The use provides support that helps ease the overall symptom burden and may assist with maintaining a sense of stability when symptoms are more noticeable.

Mepatar is commonly used across conditions presenting with inflammatory or irritative states, relevant for easing symptoms of moderately severe Acne vulgaris, and infections of the genitourinary tract like Chlamydia and Gonorrhea. It contributes to improved comfort during periods of heightened symptoms. Furthermore, it is considered relevant when supportive symptom management is appropriate for patients who experience sensitivities to certain other antibiotics.

Quick Fact: Benefit for Key Symptom Axes
Symptom Category Symptoms related to systemic imbalance and inflammatory or irritative states
Core Therapeutic Support Supports general well-being and helps ease the overall symptom load

Regulatory References

  1. NHS Tayside clinical guidance on Acne Management

Eligibility and Restrictions for Use

Eligibility for Mepatar (Oxytetracycline Class)

The official eligibility profile for Mepatar is structured around absolute contraindications and population-specific restrictions, primarily based on the drug's properties as a tetracycline-class antibiotic.

Population Status Eligibility Rule Official Classification
Hypersensitivity Cannot be used in persons with known allergy to the active substance, other tetracyclines, or any excipients. Contraindicated
Pregnancy/Lactation Prohibited for use during pregnancy (after the fourth month) and while breastfeeding. Contraindicated
Pediatric Age Use is prohibited in children under 8 years of age in most U.S. documents, or under 12 years of age in some European documents. Restricted/Not for Use
Organ Dysfunction Contraindicated in patients with severe chronic renal or hepatic dysfunction. Contraindicated
Specific Conditions Contraindicated in patients with Systemic Lupus Erythematosus (SLE) or those receiving high doses of Vitamin A or retinoid therapy (e.g., isotretinoin). Contraindicated

Eligibility Profile

Official labeling defines who must not use this medicine. Individuals with documented hypersensitivity to the drug or other tetracyclines are absolutely excluded from treatment. The medicine is contraindicated during pregnancy and lactation due to the officially recognized risk of permanent discoloration of developing teeth and potential effects on fetal bone growth. Furthermore, a strict age restriction limits use to patients above the defined pediatric age threshold (typically 8 or 12 years), also because of the risk of permanent tooth staining during the period of tooth development.

What should I know about interactions with other medicines?

Mepatar Interactions with other medicines and products

Mepatar (Oxytetracycline) has several documented interactions with other medications and products that can significantly impact its efficacy and safety. The most crucial interactions involve substances that reduce its absorption into the body, a reaction generally classified as Major in severity.

Products That Decrease Mepatar Absorption

Co-administration with antacids, supplements containing iron, zinc, calcium, or magnesium, and even common products like dairy (milk, yogurt) is strongly discouraged. These agents contain polyvalent metal cations that form non-absorbable complexes with Mepatar in the gastrointestinal tract. To minimize this effect and maintain therapeutic efficacy, Mepatar must be administered at least two to three hours apart from these substances.

Interactions Affecting Drug Levels or Effects

Use with oral anticoagulants (blood thinners) may lead to an enhanced effect of the anticoagulant, requiring close monitoring of blood clotting indices like the INR to manage an increased risk of bleeding. Concurrent use with penicillin antibiotics may also be avoided, as Mepatar's mechanism of action is theorized to interfere with the bactericidal activity of penicillins.

Additionally, Mepatar, like other tetracyclines, can potentially decrease the efficacy of hormonal oral contraceptives, necessitating the use of alternative or barrier methods for contraception during and shortly after treatment. Consult a healthcare professional to review all concurrent medications and supplements.

Mechanism of Action

Mepatar, containing oxytetracycline, functions as a protein synthesis inhibitor. The lipophilic compound facilitates its accumulation within the target cell's cytosol, primarily through passive diffusion and, in some cases, via porin channels. Its molecular target is the 30S ribosomal subunit, where it acts as a reversible inhibitor.

Binding of oxytetracycline to the 30S subunit sterically impedes the association of aminoacyl-transfer RNA (tRNA) with the ribosomal A site (aminoacyl-tRNA binding site) on the messenger RNA-ribosome complex. This specific interaction interrupts the essential elongation phase of the translational process, thereby preventing the incorporation of new amino acids into the growing polypeptide chain. This intracellular consequence leads to a downstream cascade of growth arrest. At the system level, this pharmacodynamic mechanism modulates and limits the overall population density and proliferation of susceptible cellular organisms within the affected tissues.

Dosage and Administration Information

Mepatar (Oxytetracycline hydrochloride) is administered primarily via the oral route using tablets or capsules for systemic treatment, although parenteral forms (intramuscular or intravenous injection) are available for specific severe clinical scenarios. The selection of route and form is based on the required speed of onset and the patient’s ability to take oral medication.

Dosing and Frequency

The standard adult oral dosing regimen is 250 mg every six hours (four times daily). For severe infections, this may be increased to 500 mg every six hours. The medication is generally not administered to children under 12 years of age. Dosage modification is required for patients with impaired renal function, typically by reducing the dose amount or by extending the interval between doses to prevent systemic accumulation.

Administration Conditions

Oral doses must be taken on an empty stomach to maximize absorption, necessitating administration one hour before or two hours after meals. Mepatar should be separated from dairy products and supplements containing divalent or trivalent cations (such as iron, calcium, or magnesium) by at least two to three hours, as these substances impair absorption. Tablets or capsules must be swallowed with a full glass of water while the patient is in an upright position. The typical course for acute infections continues for at least 24 to 72 hours after symptoms have resolved, or a minimum of 10 days for specific bacterial infections.

Recent Clinical Evidence

Mepatar: Recent Clinical Evidence

Evidence for Use in Moderately Severe Acne Vulgaris

Mepatar was studied for this condition in adolescents and adults using short-term and intermediate-term Randomized Controlled Trials (RCTs). These studies monitored outcomes related to inflammatory or irritative states, such as the change in inflammatory lesion counts. Findings describe patterns observed in the studies where changes in lesion counts were recorded. Long-term outcomes are not fully established regarding the durability of changes; follow-up durations were limited relative to the chronic nature of acne. Research is ongoing regarding potential antimicrobial resistance.


Evidence for Use in Genital Tract Infections (e.g., Chlamydia)

Research examined the use of Mepatar in uncomplicated infections of the genital tract, such as C. trachomatis, using controlled clinical trials in adults and adolescents. The research examined two main outcomes: microbiological cure (organism non-detection) and clinical cure (resolution of symptoms). Reports summarized the rates of organism non-detection. Comparative evidence is lacking in large, head-to-head modern trials against all newer regimens, and the impact of emerging resistance is a continuous research question.


Evidence for Use in Systemic Bacterial Conditions (e.g., Typhus and Bronchitis)

The research for typhus group infections and acute exacerbations of chronic bronchitis (AECB) largely relies on a mix of historical clinical trials and case series. Mepatar was observed in these conditions to examine outcomes like fever changes (typhus) or changes in respiratory symptoms (AECB). For typhus, the evidence base is predominantly historical. For AECB, the evidence quality varies across studies, and comparative evidence against all current alternatives is limited.


Long-Term Studies and Durability of Response

Research has explored the potential for symptoms to return after discontinuation. In general, limited information for long-term outcomes is available across all indications. The research focuses on acute or short-term end-points, and the durability of the clinical response is not as fully established.


Evidence in Special Populations

Research examined Mepatar in specific populations, with studies generally focusing on adults. Data for certain groups remain insufficient. Research focused predominantly on older populations (typically over 8 or 12 years of age). There is generally limited information for use in pregnant populations.


Research Gaps and Areas of Uncertainty

Much of the foundational evidence is historical. The overall evidence quality varies across studies, and many lack the stringent design of modern Randomized Controlled Trials (RCTs). The follow-up durations were limited, and comparative evidence is lacking for direct comparisons against the newest therapies. Research is ongoing regarding antimicrobial resistance.

Frequently Asked Questions (FAQ)

Common questions about Mepatar (FAQ)

Q: Is Mepatar considered a broad-spectrum medicine?

A: Yes, Mepatar, which contains oxytetracycline, is officially classified as a broad-spectrum antibacterial agent. This means it is used to treat a wide variety of bacterial infections that are susceptible to its action, as indicated in regulatory documents.


Q: Is it normal to feel slightly nauseous when first starting Mepatar?

A: Official product information indicates that gastrointestinal effects like nausea and vomiting are common adverse reactions associated with Mepatar. Although these are common, individuals should seek advice from a healthcare professional if the reaction is severe or persists.


Q: Are there any common side effects of Mepatar that usually go away after a few days?

A: Regulatory documents list several common and expected adverse reactions, such as nausea, vomiting, and diarrhea. However, the official product information does not specify the typical duration for how long these common effects might last.


Q: What are the most serious, but rare, side effects of Mepatar I should know about?

A: Official product warnings describe serious adverse reactions that have been reported. These include a severe increase in pressure inside the skull, known as Benign Intracranial Hypertension (Pseudotumor Cerebri), and a severe bowel inflammation called Clostridioides difficile-associated diarrhea (CDAD).


Q: Are there any specific foods or drinks, like grapefruit juice or dairy, that interact with Mepatar?

A: Official information strongly warns that taking Mepatar with dairy products and certain supplements containing metal ions (like calcium, iron, or magnesium) will significantly reduce the medicine's absorption. Grapefruit juice is not specifically mentioned in the official drug labels as a known interaction.


Q: What happens if I miss a dose of Mepatar?

A: Regulatory guidance often advises that if a dose is missed near the next scheduled time, the missed dose should be skipped, and the individual should continue with their regular schedule. It is generally advised not to take a double dose to compensate for the missed one.


Q: Does Mepatar affect my liver function?

A: Official warnings state that Mepatar is contraindicated (must not be used) in patients with severe liver dysfunction. For individuals with kidney problems, the medicine may accumulate, which can potentially lead to liver toxicity.


Q: Does Mepatar have a risk of addiction or dependence?

A: According to the official product information, Mepatar (oxytetracycline) is not classified as a controlled substance. Regulatory documents do not indicate that it carries a risk of abuse or dependence potential.


Q: Why do some people experience trouble sleeping after taking Mepatar?

A: The official adverse reaction profile includes Nervous System Disorders. However, specific common effects like insomnia or trouble sleeping are generally not listed as frequently reported adverse reactions in regulatory documents.


Q: What should I do if the medicine causes a skin rash?

A: Official product information documents that a skin rash is a known adverse reaction. In general, individuals should consult with a healthcare professional if a rash or skin reaction develops.


Q: Is Mepatar related to the drug Meprobamate or Mefloquine?

A: No. The active ingredient in Mepatar is Oxytetracycline hydrochloride. Official regulatory descriptions confirm that this substance is chemically unrelated to Meprobamate or Mefloquine.


Q: Is Mepatar affected by sun exposure or cause photosensitivity?

A: Yes, Mepatar is known to cause a photosensitivity reaction, which is an increased sensitivity of the skin to sunlight or UV light. Official warnings indicate that individuals should limit exposure to direct sunlight and artificial UV light while using this medicine.


Q: Does Mepatar cause headaches, and if so, what can be done?

A: Simple headaches are not typically listed as a common side effect. However, a severe headache may be a symptom of the serious adverse reaction known as Benign Intracranial Hypertension, which is documented in official warnings.


Q: Can Mepatar be used by people with kidney problems?

A: Official guidance states that Mepatar is contraindicated in patients with severe chronic renal dysfunction. For those with impaired renal function, individuals should consult a healthcare professional, as official guidance requires a dosage adjustment.


Q: Is it normal to feel a metallic taste in the mouth while taking Mepatar?

A: The official side effects profile for the tetracycline class sometimes includes reports of a metallic or unpleasant taste in the mouth. This is considered part of the broader gastrointestinal side effects that are documented.


Q: How does Mepatar work to treat infections/conditions?

A: Mepatar works by acting as a protein synthesis inhibitor. This action prevents the growth and replication of susceptible bacteria, which effectively stops the proliferation of the infection and allows the body's own immune system to clear the bacteria.


Q: What kind of studies or research has been done on the long-term effects of Mepatar?

A: Regulatory documents and research summaries focus heavily on the short-term safety and efficacy for treating acute infections. Official information indicates there is limited long-term data available regarding the durability of the clinical response or safety over extended periods.


Q: Can Mepatar be crushed or split if it's a tablet?

A: Official product information typically instructs users to swallow the tablets or capsules whole with a full glass of water. Regulatory instructions typically do not provide authorization for crushing or splitting the oral tablets or capsules.


Q: Are there different strengths or formulations of Mepatar available?

A: Yes, regulatory documents indicate that Mepatar is supplied in different forms. It is available as different strengths of oral tablets or capsules, as well as a sterile aqueous solution for injection.


Q: Does Mepatar have any known interactions with herbal supplements or vitamins?

A: The official label specifically warns about interactions with supplements containing polyvalent metal cations (like calcium, iron, or magnesium) because they interfere with absorption. Interactions with other specific herbal supplements are generally not listed in detail.


Q: Are there any psychological or mood side effects associated with Mepatar?

A: The adverse reaction profile includes reports of rare side effects related to the central nervous system. However, specific common psychological or mood disorders are generally not listed in the official reports.


Q: How is Mepatar cleared from the body?

A: According to official pharmacological data, Mepatar (Oxytetracycline) is primarily excreted through the kidneys (renal route). A smaller portion of the medicine is also cleared from the body through bile and feces.


Q: Is it possible to develop a tolerance to Mepatar over time?

A: Regulatory documents discuss the potential for antimicrobial resistance to develop. This is a microbiological process where the target bacteria may become less susceptible to the medicine's effects over time.


Q: Can Mepatar affect driving ability?

A: Official safety sections advise caution regarding alertness. Individuals should be aware of potential CNS side effects and avoid driving or operating machinery if their alertness is impaired.


Q: Does Mepatar have any impact on vision or hearing?

A: The severe adverse reaction Benign Intracranial Hypertension is documented to cause visual disturbances. However, a specific impact on hearing is not generally reported in official warnings.


Q: Are there any signs that Mepatar is not working for the intended purpose?

A: Clinical guidance suggests that a lack of improvement in symptoms or fever after a reasonable period of use may indicate the medicine is not working effectively. The treatment course is typically continued until clinical symptoms have resolved.


Q: What is the difference between Mepatar and a generic alternative?

A: A generic alternative contains the exact same active ingredient (Oxytetracycline hydrochloride) as Mepatar, as required by regulatory standards. The primary difference often lies in the inactive ingredients (excipients) and the manufacturer.


Q: Can Mepatar be taken alongside flu or cold remedies?

A: Official labels warn against taking Mepatar close to products containing certain minerals like antacids, iron, or zinc, as these significantly reduce its absorption. Since many common flu and cold remedies contain these components, separation is advised.

How should Mepatar be stored and disposed of?

How to Store and Dispose of Mepatar (Oxytetracycline-based)

Official regulatory guidelines dictate specific requirements for the storage and disposal of this medication, focusing on stability and environmental protection.

Storage and Stability Requirements

Requirement Official Instruction
Temperature Store at controlled room temperature (20 –25 C / 68 –77 F); protect from freezing and excessive heat.
Handling/Container Keep containers tightly closed and in the original packaging. Protect from direct sunlight.
Child Safety Store locked up and out of the reach of children.
In-Use Stability For certain injectable forms, discard unused portions 60 days after the first puncture or if the container has been punctured more than 36 times.

Disposal Instructions

Due to its classification as very toxic to aquatic life, this medication must not be released into the environment, including sewers or watercourses. Disposal of the contents and container must be done through an approved waste disposal plant in strict accordance with all local and national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mepatar found in:

A-Z Index: